Exploring the Potential of Gold Nanoparticle Technology and the Pan-Coronavirus Vaccine
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5210Keywords:
vaccine devleopment, COVID-19, pan-coronavirus vaccine, gold nanoparticle technology, R&D incentives, viral mutations, immune systems, maximizing antigens, public-private partnerships, targeted vaccine deliveriesAbstract
When facing the threat of viral COVID-19 mutations, current objectives remain rooted in creating a universal vaccine, or a pan-coronavirus vaccine, that is effective against all COVID-19 variants. While most current COVID-19 vaccines use mRNA, nonreplicating viral vectors, inactivated vaccines, and protein subunits, nanotechnology is emerging as a viable resource for developing protective immunity against COVID-19. With the possibility of new COVID-19 variants emerging, increasing funds to further gold nanoparticle research is as crucial as technological innovation. This study hypothesizes that using a combination of “push” and “pull” methods to increase R&D incentives in gold nanoparticle research can take pan-coronavirus vaccine developments one step closer to boosting long-term immunization and universal applicability. This study's limitations include the immediacy of the COVID-19 pandemic and an inability to evaluate nanotechnology vaccinations after they have been put on the market. With its emphasis on funding gold nanotechnology research via “push” and “pull” incentives, this study’s implications include furthering global partnerships and contributing to the pan-coronavirus vaccine development with sensitivity to the rising risk of mutations and immunocompromised individuals.
Downloads
References or Bibliography
Abecassis, A. (2021). Five priorities of universal COVID-19 vaccination. The Lancet, 398(10297), 285-286. https://doi.org/10.1016/S0140-6736(21)01371-4.
Beans, C. (2022). Researchers getting closer to the “universal” flu vaccine. Immunology and Inflammation, 119(5). https://doi.org/10.1073/pnas.2123477119.
Chen, G., et al. (2021). Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chemical Science, 12(20), 6929-6948. https://doi.org/10.1039/D1SC01203G.
Dimitri, N. (2012). R&D incentives for neglected diseases. PLOS ONE, 7(12), https://doi.org/10.1371/journal.pone.0050835.
Druedhal, L., et al. (2021). Collaboration in times of crisis: a study on COVID-19 vaccine R&D partnerships. Vaccine, 39(42), 6291-6295. https://doi.org/10.1016/j.vaccine.2021.08.101.
Dykman, L. A. (2020). Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. Expert Review of Vaccines, 19(5), 465-477. https://doi.org/10.1080/14760584.2020.1758070.
Fahmey, T. M., et al. (2008). Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine, 3(3), https://doi.org/10.2217/17435889.3.3.343.
Federman, R. S. (2014). Understanding vaccines: a public imperative. YJBM, 87(4), 417-422. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257029/#.
Feng, W., et al. (2022). Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine. JCLA, 36(6), https://doi.org/10.1002/jcla.24479.
Forman, R., et al. (2021). COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy, 125(5), 553-567. https://doi.org/10.1016/j.healthpol.2021.03.013.
Forni, G. & Mantovani, A. (2021). COVID-19 vaccines: where we stand and challenges ahead. Cell Death & Differentiation, 28(2), 626-639. https://doi.org/10.1038/s41418-020-00720-9.
Hagens, W. I., et al. (2007). What do we (need to) know about the kinetic properties of nanoparticles in the body? Regulatory Toxicology and Pharmacology, 49,(3) 217-229. https://doi.org/10.1016/j.yrtph.2007.07.006.
Har-Noy, H. & Or, R. (2020). Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak. Journal of Translational Medicine, 18(1), 196. https://doi.org/doi: 10.1186/s12967-020-02363-3.
Iwasaki, A. & Omer, S. B. (2020). Why and how vaccines work. Cell, 183(2), 290-295. https://doi.org/10.1016/j.cell.2020.09.040.
Keenan, J. (2023, January 7). UNMC teams exploring extended-release COVID vaccine. University of Nebraska Medical Center. https://www.unmc.edu/newsroom/2023/01/17/unmc-teams-exploring-possibility-of-extended-release-covid-vaccine/.
Lawton, G. (2021). Sights set on universal vaccine. New Scientist, 3323(27), 8-9. https://doi.org/10.1016/S0262-4079(21)00302-X.
Morens, D. M., et al. (2022). Universal coronavirus vaccines—an urgent need. The New England Journal of Medicine, 386, 297-299. https://doi.org/10.1056/NEJMp2118468.
Mueller-Langer, F. (2013). Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research? Health Economics, Policy and Law, 8(2), 185-208. https://doi.org/10.1017/S1744133112000321.
Parrett, M. (2022, April 20). Left-handed gold nanoparticles improve vaccine efficacy by more than 25 percent, finds study. European Pharmaceutical Review, https://www.europeanpharmaceuticalreview.com/news/170471/left-handed-gold-nanoparticles-improve-vaccine-efficacy-by-more-than-25-percent-finds-study/.
Pati, R., et al. (2018). Nanoparticle vaccines against infectious diseases. Frontiers in Immunology, 9, https://doi.org/10.3389/fimmu.2018.02224.
Piore, A. (2022, September 5). This nanoparticle could be the key to a universal covid vaccine. MIT Technology Review, https://www.technologyreview.com/2022/09/05/1058933/universal-covid-vaccine-research/.
Pitkethy, M. J. (2003). Nanoparticles as building blocks? Materials Today, 6(12), 36-42. https://doi.org/10.1016/S1369-7021(03)00022-1.
Pramanik, A., et al. (2021). The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles. Nanoscale Advances, 3(6), 1588-1596. https://doi.org/10.1039/D0NA01007C.
Shaik, R. A., et al. (2022). Comprehensive highlights of the universal efforts towards the development of COVID-19 vaccine. Vaccines, 10(10), 1689, https://doi.org/10.3390/vaccines10101689.
Sridhar, A., et al. (2021, June 6-11). Leveraging A Multiple-Strain Model with Mutations in Analyzing the Spread of Covid-19 [Conference presentation]. IEE, Toronto, ON, Canada. https://doi.org/10.1109/ICASSP39728.2021.9414595.
Tingley, K. (2021, December 8). We’re getting closer to ‘universal’ vaccines. it hasn’t been easy. The New York Times Magazine, https://www.nytimes.com/2021/12/08/magazine/universal-vaccines.html.
Vashishta, V. M. & Kumar, P. (2021). Looking to the future: is a universal coronavirus vaccine feasible? Expert Review of Vaccines, 21(3), 227-280. https://doi.org/10.1080/14760584.2022.2020107.
Vu, M. N., et al. (2021). Current and future nanoparticle vaccines for COVID-19. eBioMedicine: Part of the Lancelet Discovery Science, 74, https://doi.org/10.1016/j.ebiom.2021.103699.
What COVID-19 variants are going around in february 2023 (February 15, 2023). Nebraska Medicine. https://www.nebraskamed.com/COVID/what-covid-19-variants-are-going-around.
Zhao, L., et al. (2014). Nanoparticle vaccines. Vaccine, 32(3), 327-337. https://doi.org/10.1016/j.vaccine.2013.11.069.
Zimmer, C., et al. (2022, August 31). Coronavirus vaccine tracker. The New York Times, https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Chanung Lee
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
